The medicines innovation landscape according to the 2015 FDA and EMA approvals

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-D-004-Monday
• By: DELGADO-CHARRO, M Begona (University of Bath, Pharmacy and Pharmacology, Bath, United Kingdom)
• Co-author(s): M Begona Delgado-Charro: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
  Chloe Atkinson: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
  Sara Shasha’h: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
  Louise Johson: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
  Agnes Wong: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
  
• Abstract:

  Backgrounds

  Faster patient access to innovative medicines requires progress in drug discovery and development processes as well as in regulatory and HTA assessment.

  Aims

  This project explored the use the EMA and FDA public assessment reports as tools to identify key innovative trends in regulatory approvals.

  Methods

  The “2015 approvals” data set was
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login